State Street
LYEL icon

State Street’s Lyell Immunopharma LYEL Stock Holding History

State Street’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.45M Buy
72,522
+21,050
+41% +$492K ﹤0.01% 3394
2025
Q4 		$1.58M Buy
51,472
+17,720
+53% +$397K ﹤0.01% 3412
2025
Q3 		$548K Sell
33,752
-95
-0.3% -$1.08K ﹤0.01% 3643
2025
Q2 		$299K Sell
33,847
-151,275
-82% -$1.38M ﹤0.01% 3728
2025
Q1 		$1.99M Sell
185,122
-2,312
-1% -$28.3K ﹤0.01% 3249
2024
Q4 		$2.4M Sell
187,434
-7,044
-4% -$140K ﹤0.01% 3260
2024
Q3 		$5.37M Buy
194,478
+3,562
+2% +$105K ﹤0.01% 2935
2024
Q2 		$5.54M Buy
190,916
+5,018
+3% +$239K ﹤0.01% 2882
2024
Q1 		$8.29M Buy
185,898
+8,944
+5% +$383K ﹤0.01% 2690
2023
Q4 		$6.87M Sell
176,954
-163,567
-48% -$5.89M ﹤0.01% 2784
2023
Q3 		$10M Buy
340,521
+31,959
+10% +$1.52M ﹤0.01% 2598
2023
Q2 		$19.6M Sell
308,562
-87,501
-22% -$4.84M ﹤0.01% 2257
2023
Q1 		$18.7M Sell
396,063
-41,458
-9% -$2.22M ﹤0.01% 2272
2022
Q4 		$30.4M Buy
437,521
+168,529
+63% +$16.7M ﹤0.01% 1958
2022
Q3 		$39.4M Buy
268,992
+139,196
+107% +$18.8M ﹤0.01% 1769
2022
Q2 		$16.9M Buy
129,796
+35,250
+37% +$3.6M ﹤0.01% 2370
2022
Q1 		$9.55M Buy
94,546
+73,587
+351% +$8.92M ﹤0.01% 2857
2021
Q4 		$3.24M Buy
20,959
+6,769
+48% +$1.51M ﹤0.01% 3453
2021
Q3 		$4.2M Buy
+14,190
New +$4.25M ﹤0.01% 3327

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street's LYEL Position: Q1 2026 in Review

State Street increased its Lyell Immunopharma (LYEL) stake by 41% in Q1 2026, buying an estimated $492K and bringing the position to 72,522 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #3394.

State Street first reported a position in LYEL in Q3 2021 and has held it in 19 quarters since. The position peaked at $39.4M in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • State Street held 72,522 shares of Lyell Immunopharma worth $1.45M as of Q1 2026.
  • State Street bought 21,050 Lyell Immunopharma shares in Q1 2026, an estimated $492K.
  • Lyell Immunopharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3394 holding.
  • State Street first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 19 quarters since.
  • State Street's Lyell Immunopharma position peaked at $39.4M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.